Answers are grounded in this paper and cite their sources.
Demonstrates signal enhancement using a new chemiluminescence platform, suggesting improved diagnostic imaging.
Luminol chemiluminescence (CL) is widely used in bioanalysis and forensics, yet stringent alkalinity, flash-type kinetics, and blue emission strongly hinder in vivo applications. Here, we report QC4A-8C, a single compartmentalized supramolecular platform that simultaneously addresses these limitations. QC4A-8C is an amphiphilic quaternary ammonium calix[4]arene with orthogonally functionalized upper and lower rims. The cationic cavity selectively encapsulates luminol, induces a pKa shift, and converts luminol into a glow-type emitter at near-physiological pH. In parallel, the hydrophobic lower rim self-assembles into nanoaggregates that compartmentalize fluorescent acceptors (DTBT, MCCH, DCI) in nanometer proximity, enabling sequential chemiluminescence resonance energy transfer (CRET) with high efficiency and red-shifted emission (650-700 nm). As a result, tissue penetration and emission lifetime are substantially extended, and in a lipopolysaccharide-induced peritonitis model, QC4A-8C delivers pronounced signal enhancement over free luminol. This work validates macrocyclic host-guest chemistry as a programmable route to integrate CL amplification with optical spectral engineering for diagnostic imaging.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: